{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:08:00Z","timestamp":1789236480924,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2023C03111"],"award-info":[{"award-number":["2023C03111"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019540","name":"Science Fund for Distinguished Young Scholars of Zhejiang Province","doi-asserted-by":"publisher","award":["LR21H300003"],"award-info":[{"award-number":["LR21H300003"]}],"id":[{"id":"10.13039\/501100019540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019540","name":"Science Fund for Distinguished Young Scholars of Zhejiang Province","doi-asserted-by":"publisher","award":["LR22H310002"],"award-info":[{"award-number":["LR22H310002"]}],"id":[{"id":"10.13039\/501100019540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103975"],"award-info":[{"award-number":["82103975"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173660"],"award-info":[{"award-number":["82173660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ21H300005"],"award-info":[{"award-number":["LQ21H300005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.apsb.2025.01.021","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:40:05Z","timestamp":1738258805000},"page":"1659-1679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0516-3293","authenticated-orcid":false,"given":"Yuheng","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-2289","authenticated-orcid":false,"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-8970","authenticated-orcid":false,"given":"Yushen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuqiu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiting","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-6404","authenticated-orcid":false,"given":"Ji","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-4372","authenticated-orcid":false,"given":"Xiaowu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.01.021_bib1","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semcancer.2020.11.005","article-title":"Anticancer properties of chimeric HDAC and kinase inhibitors","volume":"83","author":"Biersack","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.apsb.2025.01.021_bib4","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/febs.13061","article-title":"Class IIa HDACs\u2015new insights into their functions in physiology and pathology","volume":"282","author":"Parra","year":"2015","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2025.01.021_bib5","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.chembiol.2021.07.002","article-title":"Chemo-proteomics exploration of HDAC degradability by small molecule degraders","volume":"28","author":"Xiong","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.01.021_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00018-014-1727-8","article-title":"Selective class IIa HDAC inhibitors: myth or reality","volume":"72","author":"Di Giorgio","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2025.01.021_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1074\/mcp.O114.046565","article-title":"Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease","volume":"14","author":"Mathias","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.apsb.2025.01.021_bib8","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/febs.16437","article-title":"Histone deacetylase 7: a signaling hub controlling development, inflammation, metabolism and disease","volume":"290","author":"Wang","year":"2023","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2025.01.021_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2212813120","article-title":"HDAC7 is an immunometabolic switch triaging danger signals for engagement of antimicrobial versus inflammatory responses in macrophages","volume":"120","author":"Das Gupta","year":"2023","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2025.01.021_bib10","doi-asserted-by":"crossref","first-page":"F1015","DOI":"10.1152\/ajprenal.00405.2020","article-title":"Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury","volume":"319","author":"Zhang","year":"2020","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.apsb.2025.01.021_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13046-022-02266-9","article-title":"HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of \u03b2-catenin-FGF18 pathway","volume":"41","author":"Guo","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.01.021_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12943-017-0736-2","article-title":"HDAC7 promotes lung tumorigenesis by inhibiting STAT3 activation","volume":"16","author":"Lei","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.01.021_bib13","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1038\/s41388-019-0897-0","article-title":"HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells","volume":"38","author":"Caslini","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.01.021_bib14","first-page":"54","article-title":"Melatonin inhibits ESCC tumor growth by mitigating the HDAC7\/\u03b2-catenin\/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability","volume":"9","author":"Ma","year":"2022","journal-title":"Mil Med Res"},{"key":"10.1016\/j.apsb.2025.01.021_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.01.021_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.594","article-title":"The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma","volume":"6","author":"Barneda-Zahonero","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.01.021_bib17","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1084\/jem.20150821","article-title":"In\u00a0vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development","volume":"213","author":"Azagra","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.01.021_bib18","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/leu.2015.83","article-title":"Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma","volume":"29","author":"Kikuchi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2025.01.021_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034577","article-title":"Comprehensive analysis of HDAC7 expression and its prognostic value in diffuse large B cell lymphoma: a review","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.apsb.2025.01.021_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317720643","article-title":"Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia","volume":"39","author":"Jamalpour","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.apsb.2025.01.021_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13543776.2023.2219393","article-title":"An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020\u2012present)","volume":"33","author":"Liu","year":"2023","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2025.01.021_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2025.01.021_bib23","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2025.01.021_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2025.01.021_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115759","article-title":"Rational discovery of dual FLT3\/HDAC inhibitors as a potential AML therapy","volume":"260","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115907","article-title":"5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib","volume":"263","author":"Asfaha","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2025.01.021_bib28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1021\/jm401945k","article-title":"Improved synthesis and structural reassignment of MC1568: a class IIa selective HDAC inhibitor","volume":"57","author":"Fleming","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bmcl.2018.11.009","article-title":"Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor","volume":"29","author":"Luckhurst","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.021_bib30","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.2174\/0929867328666210629160647","article-title":"Targeting class IIa HDACs: insights from phenotypes and inhibitors","volume":"28","author":"Liu","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115087","article-title":"Recent advances in class IIa histone deacetylases research","volume":"27","author":"Asfaha","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib32","article-title":"Recent update of HDAC inhibitors in lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2025.01.021_bib33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","article-title":"HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma","volume":"11","author":"Wang","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2025.01.021_bib34","doi-asserted-by":"crossref","first-page":"26694","DOI":"10.1074\/jbc.M803514200","article-title":"Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain","volume":"283","author":"Bottomley","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1101\/gad.14.1.45","article-title":"Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway","volume":"14","author":"Huang","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2025.01.021_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017\u2012present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2025.01.021_bib37","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.01.021_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic\u2015a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2025.01.021_bib39","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1039\/D2MD00199C","article-title":"A \u2018click\u2019 chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras","volume":"13","author":"Cross","year":"2022","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib40","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1021\/acs.jmedchem.1c02179","article-title":"Optimization of class I histone deacetylase PROTACs reveals that HDAC1\/2 degradation is critical to induce apoptosis and cell arrest in cancer cells","volume":"65","author":"Smalley","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib41","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1039\/D0CC03243C","article-title":"Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs","volume":"56","author":"Xiao","year":"2020","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2025.01.021_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310059","article-title":"Histone Deacetylase 3-directed PROTACs have anti-inflammatory potential by blocking polarization of M0-like into M1-like macrophages","volume":"62","author":"Zhao","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.01.021_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2023.07.010","article-title":"HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation","volume":"30","author":"Xiao","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.01.021_bib44","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s13238-018-0602-z","article-title":"Developing potent PROTACs tools for selective degradation of HDAC6 protein","volume":"10","author":"An","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2025.01.021_bib45","doi-asserted-by":"crossref","first-page":"16860","DOI":"10.1021\/acs.jmedchem.2c01659","article-title":"Solid-phase synthesis of cereblon-recruiting selective Histone Deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity","volume":"65","author":"Sinatra","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acs.jmedchem.2c00739","article-title":"Structure-based discovery of selective Histone Deacetylase 8 degraders with potent anticancer activity","volume":"66","author":"Huang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114544","article-title":"Discovery of pomalidomide-based PROTACs for selective degradation of Histone Deacetylase 8","volume":"239","author":"Sun","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of Sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib49","doi-asserted-by":"crossref","first-page":"12445","DOI":"10.1021\/acs.jmedchem.2c01149","article-title":"Developing HDAC4-selective protein degraders to investigate the role of HDAC4 in Huntington's disease pathology","volume":"65","author":"Macabuag","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib50","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1021\/acs.jmedchem.1c00900","article-title":"Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"64","author":"Xiang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib51","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1021\/acs.jmedchem.2c00324","article-title":"Structural feature analyzation strategies toward discovery of orally bioavailable PROTACs of Bruton's Tyrosine Kinase for the treatment of lymphoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.01.021_bib53","doi-asserted-by":"crossref","first-page":"22045","DOI":"10.1074\/jbc.M201736200","article-title":"Class II histone deacetylases are directly recruited\u00a0by\u00a0BCL6 transcriptional repressor","volume":"277","author":"Lemercier","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.01.021_bib54","doi-asserted-by":"crossref","first-page":"14831","DOI":"10.1073\/pnas.96.26.14831","article-title":"Recruitment of SMRT\/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB\/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B","volume":"96","author":"Deltour","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:16:33Z","timestamp":1762604193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2211383525000279"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.01.021","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}